Chairman’s Open Letter to Shareholders

AI SummaryClose X

ImmuPharma PLC has successfully completed a fundraising, with shareholders approving resolutions for a £6 million Lanstead subscription and a £468,000 WRAP retail offering, significantly strengthening the company's balance sheet and extending its cash runway to at least H2 2028. This capital will advance strategic priorities, including securing a value-enhancing partnering agreement for its P140 auto-immune technology platform in 2026 and accelerating the development program for Kapiglucagon for type 1 diabetes. The Lanstead subscription includes a Sharing Arrangement with an 8p Benchmark Price, potentially allowing the company to benefit from future share price performance.

Disclaimer*

Companies

Immupharma (IMM)
UK 100

Latest directors dealings